相关实验视频

Updated: Jun 4, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

作为抗抑郁药不响应者的下一步,rTMS的成本效益:与当前抗抑郁药治疗方法的随机比较

Iris Dalhuisen^1,2, Kim Bui^3,4, Anne Kleijburg^4,5

¹Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands.

Acta psychiatrica Scandinavica

|December 22, 2024

概括

相比于药物治疗,重复性横磁性刺激 (rTMS) 是治疗耐药抑郁症的经济有效的治疗方法. 这种方法提供了更高的质量调整寿命年 (QALYs) 和更好的缓解率,成本更低.

科学领域:

神经科学是一个神经科学.
精神病学是一个精神病学.
卫生经济学卫生经济学

背景情况:

耐治疗抑郁症 (TRD) 构成了重大挑战,现有治疗方法的成本效益研究有限.
重复性横磁性刺激 (rTMS) 是TRD的一种成熟治疗方法,但与药物治疗等其他选择相比,其经济价值尚未得到充分研究.

研究的目的:

进行对rTMS与TRD标准药物治疗进行比较的经济评估.
在12个月的随访期内评估rTMS的成本效益和成本效益.

主要方法:

在荷兰医疗保健机构进行了一项实用性的多中心随机对照试验.
患有TRD的患者随机分配到接受rTMS或药理治疗算法的下一步.
经济评估包括计算增量成本效益比率 (ICER) 和增量成本效益比率 (ICUR),使用单次归算缺失的数据.

主要成果:

与药物组相比,rTMS组显示出更高的质量调整寿命年 (QALYs) (0.618对0.545) 和更好的反应 (27.1%对24.4%) 和缓解率 (25.0%对17.1%).
rTMS导致总体成本降低,增量成本为-2 280.0欧元.
这些发现表明,在rTMS方面,增量成本效益比率 (ICUR) 和增量成本效益比率 (ICER) 占主导地位.

结论:

相比于随后的药理干预措施,重复性跨磁刺激 (rTMS) 是治疗耐药抑郁症患者的经济有效的治疗选择.
这项研究支持将rTMS整合到抑郁症治疗算法中,提供了有利的经济和临床概况.

关键词:

有关RCT的RCT是什么抗抑郁药是一种抗抑郁药.经济效益性成本效益性大型抑郁症主要是抑郁症.rTMSMS是因为

更多相关视频

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

相关概念视频

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...